Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 17 de 17
Filtrer
1.
Food Res Int ; 173(Pt 1): 113252, 2023 11.
Article de Anglais | MEDLINE | ID: mdl-37803565

RÉSUMÉ

Sorghum BRS 305 (Sorghum bicolor L. Moench) is a cereal with high tannins and anthocyanins content and keep better the resistant starch when submitted to dry heat treatment. Our objective was to investigate the effects of BRS 305 dry heat treatment whole sorghum flour on satiety and antioxidant response in brain and adipose tissue of Wistar rats fed with a high fat high fructose diet (HFHF). Male Wistar rats were divided in two groups: control (n = 8) and HFHF (n = 16) for eight weeks. After, animals of HFHF group were divided: HFHF (n = 8) and HFHF + BRS 305 sorghum whole flour (n = 8), for 10 weeks. Sorghum consumption reduced gene expression of leptin, resistin, and endocannabinoid receptor 1 type (CB1) in adipose and brain tissues compared to HFHF group. In brain, sorghum consumption also promotes reduction in neuropeptide Y (NPY) gene expression. BRS305 sorghum consumption improved gene expression of sirtuin-1 (SIRT1) in adipose tissue, and in the brain increased heat shock protein 72 (HSP72), erythroid-derived nuclear factor 2 (NRF2), peroxisome proliferator-activated receptor alpha (PPARα), superoxide dismutase (SOD) and catalase activity compared to HFHF. In silicoanalysis showed interaction with PPARα, CB1, and leptin receptors. Advanced glycation end products (AGEs) concentrations in group HFHF + sorghum did not differ from HFHF group. Advanced glycation end products receptors (RAGEs) concentrations did not differ among experimental groups. Then, BRS 305 sorghum submitted to dry treatment was able to modulate gene expression of markers related to satiety and improve antioxidant capacity of rats fed with HFHF diet.


Sujet(s)
Antioxydants , Sorghum , Rats , Mâle , Animaux , Rat Wistar , Antioxydants/analyse , Sorghum/composition chimique , Farine/analyse , Grains comestibles/composition chimique , Fructose/analyse , Récepteur PPAR alpha , Anthocyanes/analyse , Alimentation riche en graisse/effets indésirables , Encéphale , Produits terminaux de glycation avancée/analyse
2.
Braz. J. Pharm. Sci. (Online) ; 59: e23017, 2023. tab, graf
Article de Anglais | LILACS | ID: biblio-1505848

RÉSUMÉ

Abstract Infusion solutions must be stable from the production stage until the infusion stage. Some infusion fluids contain degradation products, known as advanced glycation end products (AGEs); however, it is unknown whether AGEs exist in parenteral nutrition solutions. We aimed to investigate this question and test the effect of infusion conditions on AGE formation in parenteral nutrition solution. Nine parenteral nutrition solutions were supplied by the pharmacy with which we collaborated. To simulate the infusion conditions, the solutions were held in a patient room with standard lighting and temperature for 24 hours. Samples were taken at the beginning (group A) and the end (24th hour, group B) of the infusion period. The degradation products were 3-deoxyglucosone, pentosidine, N-carboxymethyl lysine, and 4-hydroxynonenal, which we investigated by high-performance liquid chromatography-mass spectrometry (LC-MS) and Q-TOF LC/MS methods. Two of four degradation products, 4-hydroxynonenal and N-carboxymethyl lysine, were detected in all samples, and Group B had higher levels of both compounds compared to Group A, who showed that the quantities of these compounds increased in room conditions over time. The increase was significant for 4-hydroxynonenal (p=0.03), but not for N-carboxymethyl lysine (p=0.23). Moreover, we detected in the parenteral nutrition solutions a compound that could have been 4-hydroxy-2-butynal or furanone


Sujet(s)
Nutrition parentérale/effets indésirables , Produits terminaux de glycation avancée/analyse , Solutions d'alimentation parentérale/administration et posologie , Pharmacie/classification , Spectrométrie de masse/méthodes , Chambre de patient/classification , Éclairage/classification , Chromatographie en phase liquide à haute performance/méthodes
3.
PLoS One ; 17(1): e0262369, 2022.
Article de Anglais | MEDLINE | ID: mdl-35061788

RÉSUMÉ

Glycation process refers to reactions between reduction sugars and amino acids that can lead to formation of advanced glycation end products (AGEs) which are related to changes in chemical and functional properties of biological structures that accumulate during aging and diseases. The aim of this study was to perform and analyze in vitro glycation by fructose and methylglyoxal (MGO) using salivary fluid, albumin, lysozyme, and salivary α-amylase (sAA). Glycation effect was analyzed by biochemical and spectroscopic methods. The results were obtained by fluorescence analysis, infrared spectroscopy (total attenuated reflection-Fourier transform, ATR-FTIR) followed by multivariate analysis of principal components (PCA), protein profile, immunodetection, enzymatic activity and oxidative damage to proteins. Fluorescence increased in all glycated samples, except in saliva with fructose. The ATR-FTIR spectra and PCA analysis showed structural changes related to the vibrational mode of glycation of albumin, lysozyme, and salivary proteins. Glycation increased the relative molecular mass (Mr) in protein profile of albumin and lysozyme. Saliva showed a decrease in band intensity when glycated. The analysis of sAA immunoblotting indicated a relative reduction in intensity of its correspondent Mr after sAA glycation; and a decrease in its enzymatic activity was observed. Carbonylation levels increased in all glycated samples, except for saliva with fructose. Thiol content decreased only for glycated lysozyme and saliva with MGO. Therefore, glycation of salivary fluid and sAA may have the potential to identify products derived by glycation process. This opens perspectives for further studies on the use of saliva, an easy and non-invasive collection fluid, to monitor glycated proteins in the aging process and evolution of diseases.


Sujet(s)
Fructose/analyse , Produits terminaux de glycation avancée/métabolisme , Méthylglyoxal/analyse , Adulte , Albumines/analyse , Albumines/composition chimique , Femelle , Produits terminaux de glycation avancée/analyse , Glycosylation , Volontaires sains , Humains , Mâle , Lysozyme/analyse , Lysozyme/composition chimique , Stress oxydatif , Salive/composition chimique , Protéines et peptides salivaires/métabolisme , Spectrométrie de fluorescence
4.
Nutrients ; 13(8)2021 Aug 16.
Article de Anglais | MEDLINE | ID: mdl-34444961

RÉSUMÉ

Most chronic modern non-transmissible diseases seem to begin as the result of low-grade inflammation extending over prolonged periods of time. The importance of diet as a source of many pro-inflammatory compounds that could create and sustain such a low-grade inflammatory state cannot be ignored, particularly since we are constantly exposed to them during the day. The focus of this review is on specific components of the diet associated with inflammation, specifically advanced glycation end products (AGEs) that form during thermal processing of food. AGEs are also generated in the body in normal physiology and are widely recognized as increased in diabetes, but many people are unaware of the potential importance of exogenous AGEs ingested in food. We review experimental models, epidemiologic data, and small clinical trials that suggest an important association between dietary intake of these compounds and development of an inflammatory and pro-oxidative state that is conducive to chronic diseases. We compare dietary intake of AGEs with other widely known dietary patterns, such as the Mediterranean and the Dietary Approaches to Stop Hypertension (DASH) diets, as well as the Dietary Inflammation Index (DII). Finally, we delineate in detail the pathophysiological mechanisms induced by dietary AGEs, both direct (i.e., non-receptor-mediated) and indirect (receptor-mediated).


Sujet(s)
Régime alimentaire/statistiques et données numériques , Produits terminaux de glycation avancée/analyse , Inflammation , Humains , Inflammation/sang , Inflammation/métabolisme
5.
J Bras Nefrol ; 39(3): 253-260, 2017.
Article de Anglais, Portugais | MEDLINE | ID: mdl-28902232

RÉSUMÉ

INTRODUCTION: Chronic kidney disease (CKD) is associated with high morbidity and mortality rates, main causes related with cardiovascular disease (CVD) and bone mineral disorder (CKD-BMD). Uremic toxins, as advanced glycation end products (AGEs), are non-traditional cardiovascular risk factor and play a role on development of CKD-BMD in CKD. The measurement of skin autofluorescence (sAF) is a noninvasive method to assess the level of AGEs in tissue, validated in CKD patients. OBJECTIVE: The aim of this study is analyze AGEs measured by sAF levels (AGEs-sAF) and its relations with CVD and BMD parameters in HD patients. METHODS: Twenty prevalent HD patients (HD group) and healthy subjects (Control group, n = 24), performed biochemical tests and measurements of anthropometric parameters and AGEs-sAF. In addition, HD group performed measurement of intact parathormone (iPTH), transthoracic echocardiogram and radiographies of pelvis and hands for vascular calcification score. RESULTS: AGEs-sAF levels are elevated both in HD and control subjects ranged according to the age, although higher at HD than control group. Single high-flux HD session does not affect AGEs-sAF levels. AGEs-sAF levels were not related to ventricular mass, interventricular septum or vascular calcification in HD group. AGEs-sAF levels were negatively associated with serum iPTH levels. CONCLUSION: Our study detected a negative correlation of AGEs-sAF with serum iPTH, suggesting a role of AGEs on the pathophysiology of bone disease in HD prevalent patients. The nature of this relation and the clinical application of this non-invasive methodology for evaluation AGEs deposition must be confirmed and clarified in future studies.


Sujet(s)
Ostéodystrophie rénale/métabolisme , Produits terminaux de glycation avancée/métabolisme , Peau/métabolisme , Adulte , Ostéodystrophie rénale/imagerie diagnostique , Études transversales , Femelle , Produits terminaux de glycation avancée/analyse , Humains , Mâle , Imagerie optique , Projets pilotes , Peau/imagerie diagnostique
6.
J. bras. nefrol ; 39(3): 253-260, July-Sept. 2017. tab, graf
Article de Anglais | LILACS | ID: biblio-893773

RÉSUMÉ

Abstract Introduction: Chronic kidney disease (CKD) is associated with high morbidity and mortality rates, main causes related with cardiovascular disease (CVD) and bone mineral disorder (CKD-BMD). Uremic toxins, as advanced glycation end products (AGEs), are non-traditional cardiovascular risk factor and play a role on development of CKD-BMD in CKD. The measurement of skin autofluorescence (sAF) is a noninvasive method to assess the level of AGEs in tissue, validated in CKD patients. Objective: The aim of this study is analyze AGEs measured by sAF levels (AGEs-sAF) and its relations with CVD and BMD parameters in HD patients. Methods: Twenty prevalent HD patients (HD group) and healthy subjects (Control group, n = 24), performed biochemical tests and measurements of anthropometric parameters and AGEs-sAF. In addition, HD group performed measurement of intact parathormone (iPTH), transthoracic echocardiogram and radiographies of pelvis and hands for vascular calcification score. Results: AGEs-sAF levels are elevated both in HD and control subjects ranged according to the age, although higher at HD than control group. Single high-flux HD session does not affect AGEs-sAF levels. AGEs-sAF levels were not related to ventricular mass, interventricular septum or vascular calcification in HD group. AGEs-sAF levels were negatively associated with serum iPTH levels. Conclusion: Our study detected a negative correlation of AGEs-sAF with serum iPTH, suggesting a role of AGEs on the pathophysiology of bone disease in HD prevalent patients. The nature of this relation and the clinical application of this non-invasive methodology for evaluation AGEs deposition must be confirmed and clarified in future studies.


Resumo Introdução: A doença renal crônica (DRC) apresenta elevadas taxas de morbidade e mortalidade, sendo a doença cardiovascular (DCV) e o distúrbio mineral e ósseo da DRC (DMO-DRC) complicações frequentes. As toxinas urêmicas, dentre elas os produtos finais da glicação avançada (AGEs), são fatores de risco cardiovascular não tradicionais e se encontram envolvidas no desenvolvimento do DMO-DRC na DRC. A medida da autofluorescência da pele (sAF) é método não invasivo para quantificação do acúmulo tecidual de AGEs validado em pacientes portadores de DRC. Objetivos: O objetivo deste estudo é avaliar as relações entre os AGEs medidos por sAF (AGEs-AF) e parâmetros de DCV e DMO-DRC em pacientes em hemodiálise (HD). Métodos: 20 pacientes em HD (grupo HD) e 24 indivíduos hígidos (grupo controle) foram submetidos à análise bioquímica sérica, medidas antropométricas e de sAF. O grupo HD realizou medida de hormônio intacto da paratireoide (PTHi), ecocardiograma transtorácico e radiografias de pelve e mãos para pesquisa de calcificação vascular. Resultados: Os níveis de AGEs-sAF foram elevados para a idade nos grupos HD e controle, porém mais elevados no grupo HD. Sessão única de HD de alto-fluxo não afetou os níveis de AGEs-sAF. Os níveis teciduais de AGEs não se correlacionaram com massa ventricular, espessura de septo interventricular ou calcificação vascular no grupo HD. Os níveis de AGEs-sAF se correlacionaram negativamente com os níveis séricos de PTHi. Conclusão: Nosso estudo detectou correlação negativa entre os níveis de AGEs-sAF e os níveis séricos de PTHi, sugerindo que os AGEs estejam envolvidos na fiosiopatologia da doença óssea em pacientes em HD. A natureza desta relação e a aplicação clínica deste método não invasivo de avaliação do acúmulo tecidual de AGEs deve ser confirmada e elucidada por estudos futuros.


Sujet(s)
Humains , Mâle , Femelle , Adulte , Ostéodystrophie rénale/métabolisme , Peau/métabolisme , Produits terminaux de glycation avancée/métabolisme , Ostéodystrophie rénale/imagerie diagnostique , Peau/imagerie diagnostique , Projets pilotes , Études transversales , Produits terminaux de glycation avancée/analyse , Imagerie optique
7.
PLoS One ; 12(6): e0179654, 2017.
Article de Anglais | MEDLINE | ID: mdl-28628674

RÉSUMÉ

BACKGROUND: This study aimed to investigate the pathophysiology of hepatic microcirculatory dysfunction in non-alcoholic fatty liver disease (NAFLD). METHODS: In Wistar rats, NAFLD model was induced by 20 weeks of high-fat diet (HFD) feeding. Rolling and adhesion of leukocytes and tissue perfusion in hepatic microcirculation were examined using in vivo microscopic and laser speckle contrast imaging (LSCI), respectively. Oxidative stress and inflamatory parameters were analysed by TBARs, catalase enzyme activity, RT-PCR and ELISA. The participation of advanced glycation end-products (AGE) and its receptor RAGE was evaluated by the measurement of gene and protein expression of RAGE by RT-PCR and Western-blot, respectively and by liver and serum quantification of fluorescent AGEs. RESULTS: Wistar rats fed high-fat diet (HFD) showed increase in epididymal and abdominal fat content, systolic arterial blood pressure, fasting blood glucose levels, hepatic triglycerides and cholesterol, and impairment of glucose and insulin metabolisms. Liver histology confirmed the presence of steatosis and ultrasound analysis revealed increased liver size and parenchymal echogenicity in HFD-fed rats. HFD causes significant increases in leukocyte rolling and adhesion on hepatic microcirculation and decrease in liver microvascular blood flow. Liver tissue presented increase in oxidative stress and inflammtion. At 20 weeks, there was a significantly increase in AGE content in the liver and serum of HFD-fed rats and an increase in RAGE gene expression in the liver. CONCLUSION: The increase in liver AGE levels and microcirculatory disturbances could play a role in the pathogenesis of liver injury and are key components of NAFLD.


Sujet(s)
Produits terminaux de glycation avancée/analyse , Foie/métabolisme , Microcirculation/physiologie , Stéatose hépatique non alcoolique/anatomopathologie , Animaux , Glycémie/analyse , Pression sanguine/physiologie , Catalase/analyse , Catalase/génétique , Catalase/métabolisme , Cholestérol/sang , Alimentation riche en graisse , Interleukine-1 bêta/sang , Leucocytes/cytologie , Leucocytes/métabolisme , Foie/vascularisation , Foie/imagerie diagnostique , Mâle , Stéatose hépatique non alcoolique/métabolisme , Stress oxydatif , Rats , Rat Wistar , Réaction de polymérisation en chaine en temps réel , Récepteur spécifique des produits finaux de glycosylation avancée/génétique , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Triglycéride/sang , Facteur de nécrose tumorale alpha/sang
8.
Adv Nutr ; 6(4): 461-73, 2015 Jul.
Article de Anglais | MEDLINE | ID: mdl-26178030

RÉSUMÉ

Over the past 2 decades there has been increasing evidence supporting an important contribution from food-derived advanced glycation end products (AGEs) to the body pool of AGEs and therefore increased oxidative stress and inflammation, processes that play a major role in the causation of chronic diseases. A 3-d symposium (1st Latin American Symposium of AGEs) to discuss this subject took place in Guanajuato, Mexico, on 1-3 October 2014 with the participation of researchers from several countries. This review is a summary of the different presentations and subjects discussed, and it is divided into 4 sections. The first section deals with current general knowledge about AGEs. The second section dwells on mechanisms of action of AGEs, with special emphasis on the receptor for advanced glycation end products and the potential role of AGEs in neurodegenerative diseases. The third section discusses different approaches to decrease the AGE burden. The last section discusses current methodologic problems with measurement of AGEs in different samples. The subject under discussion is complex and extensive and cannot be completely covered in a short review. Therefore, some areas of interest have been left out because of space. However, we hope this review illustrates currently known facts about dietary AGEs as well as pointing out areas that require further research.


Sujet(s)
Maladie chronique , Régime alimentaire , Produits terminaux de glycation avancée , État de santé , Agriculture/méthodes , Cuisine (activité)/méthodes , Exercice physique , Aliments , Manipulation des aliments/méthodes , Produits terminaux de glycation avancée/effets indésirables , Produits terminaux de glycation avancée/analyse , Produits terminaux de glycation avancée/physiologie , Température élevée , Humains , Inflammation , Lysine/analogues et dérivés , Lysine/analyse , Mexique , Maladies neurodégénératives , Stress oxydatif , Récepteur spécifique des produits finaux de glycosylation avancée/physiologie , Solubilité
9.
Diabetes Care ; 33(10): 2232-7, 2010 Oct.
Article de Anglais | MEDLINE | ID: mdl-20628088

RÉSUMÉ

OBJECTIVE: Proinflammatory advanced glycation end products (AGEs) found in thermally processed foods correlate with serum AGEs (sAGEs) and promote type 1 and type 2 diabetes in mice. Herein we assess the relationship of maternal blood and food AGEs to circulating glycoxidants, inflammatory markers, and insulin levels in infants up to age 1 year. RESEARCH DESIGN AND METHODS: AGEs (N(ε)-carboxymethyllysine [CML] and methylglyoxal derivatives) were tested in sera of healthy mothers in labor (n = 60), their infants, and infant foods. Plasma 8-isoprostane, fasting glucose, insulin, leptin, and adiponectin levels were assessed in 12-month-old infants. RESULTS: Significant correlations were found between newborn and maternal serum CML (sCML) (r = 0.734, P = 0.001) serum methylglyoxal derivatives (sMGs) (r = 0.593, P = 0.001), and 8-isoprostanes (r = 0.644, P = 0.001). Infant adiponectin at 12 months negatively correlated with maternal sCML (r = -0.467, P = 0.011), whereas high maternal sMGs predicted higher infant insulin or homeostasis model assessment (P = 0.027). Infant sAGEs significantly increased with the initiation of processed infant food intake, raising daily AGE consumption by ∼7.5-fold in year 1. CONCLUSIONS: Maternal blood and food-derived AGEs prematurely raise AGEs in children to adult norms, preconditioning them to abnormally high oxidant stress and inflammation and thus possibly to early onset of disease, such as diabetes.


Sujet(s)
Diabète de type 1/étiologie , Diabète de type 2/étiologie , Produits terminaux de glycation avancée/métabolisme , Adiponectine/sang , Adolescent , Adulte , Diabète de type 1/sang , Diabète de type 1/métabolisme , Diabète de type 2/sang , Diabète de type 2/métabolisme , Femelle , Produits terminaux de glycation avancée/administration et posologie , Produits terminaux de glycation avancée/analyse , Humains , Nourrisson , Aliment du nourrisson au cours de la première année/analyse , Nouveau-né , Insuline/sang , Isoprosane/sang , Lysine/analogues et dérivés , Lysine/sang , Méthylglyoxal/sang , Facteurs de risque , Jeune adulte
10.
Mol Cell Biochem ; 341(1-2): 33-41, 2010 Aug.
Article de Anglais | MEDLINE | ID: mdl-20309613

RÉSUMÉ

Advanced glycation end-products (AGEs) are heterogeneous groups of compounds that result from the non-enzymatic reaction of reducing sugars with free amino groups of biological molecules such as proteins, lipids, and nucleic acids. A large number of studies have been focused on AGEs metabolism, analysis, treatments, and their implications in the pathogenesis of diseases, especially in diabetes mellitus. Here, we review recent advances in the understanding of pathological complications caused by the production of AGEs. We provide an overview of the most important issues published within this area in last years; we also present the number of scientific papers related to AGEs available since 1950 until 2008 in the most important fields including metabolism, physiology, and pharmacology, thus as analytical methods for AGE detection and quantification and studies carried out in human body fluids. Data were collected from ovidSP.


Sujet(s)
Diabète/métabolisme , Produits terminaux de glycation avancée , Recherche/tendances , Complications du diabète/métabolisme , Produits terminaux de glycation avancée/analyse , Produits terminaux de glycation avancée/biosynthèse , Produits terminaux de glycation avancée/physiologie , Humains
11.
Arq Bras Endocrinol Metabol ; 52(6): 940-50, 2008 Aug.
Article de Portugais | MEDLINE | ID: mdl-18820805

RÉSUMÉ

The advanced glycation end-products (AGEs) constitute a class of heterogeneous molecules formed by amino-carbonyl reactions of a non-enzymatic nature, which occur at an accelerated rate in the hyperglycemic state of diabetes. Considered important pathogenic mediators of diabetic complications, AGEs are capable of irreversibly modifying the chemical properties and functions of diverse biological structures. In this review, recent data from literature is presented describing the pathways of AGEs formation, their metabolism, the main mechanisms of action of these substances in the triggering of pathological processes associated with diabetes, as well as methods of AGEs determination in biological samples. This text also points to new perspectives in anti-AGE therapies, an example of which is the studies involved with the action of natural compounds of food, which can represent a potential coadjuvant therapy for people with diabetes or other pathologies associated with the degenerative accumulation of AGEs.


Sujet(s)
Artériolosclérose/étiologie , Angiopathies diabétiques/étiologie , Produits terminaux de glycation avancée/physiologie , Antioxydants/usage thérapeutique , Néphropathies diabétiques/étiologie , Neuropathies diabétiques/étiologie , Rétinopathie diabétique/étiologie , Aliments , Produits terminaux de glycation avancée/analyse , Produits terminaux de glycation avancée/antagonistes et inhibiteurs , Humains
12.
Blood Purif ; 26(2): 204-10, 2008.
Article de Anglais | MEDLINE | ID: mdl-18285696

RÉSUMÉ

Inflammatory markers predict mortality in hemodialysis (HD) patients, whereas a possible association between oxidative stress (OS) markers and survival is less clear. We assessed the impact on all-cause mortality of baseline inflammatory [high-sensitivity C-reactive protein and interleukin-6 (IL-6)] and OS markers (advanced oxidation protein products, pentosidine, homocysteine) in 112 HD patients. We found no significant correlations between inflammatory and OS markers. During the 5.5 years of follow-up, 51 patients died. In a Kaplan-Meier analysis, the survival rate was reduced in patients with IL-6 higher than the median (IL-6 >4.2 pg/ml) (log- rank = 6.47; p = 0.01), in diabetics (log-rank = 12.26; p = 0.0005) and in older patients (log-rank = 11.22; p = 0.0008). Moreover, in Cox analysis only IL-6 and age were independently associated with mortality. We conclude that in this group of prevalent Brazilian HD patients, IL-6 was a better predictor of survival than other inflammatory and OS markers.


Sujet(s)
Interleukine-6/sang , Défaillance rénale chronique/mortalité , Dialyse rénale , Adulte , Arginine/analogues et dérivés , Arginine/analyse , Protéine C-réactive/analyse , Femelle , Produits terminaux de glycation avancée/analyse , Homocystéine/analyse , Humains , Défaillance rénale chronique/diagnostic , Lysine/analogues et dérivés , Lysine/analyse , Mâle , Adulte d'âge moyen , Oxydoréduction , Pronostic , Protéines/métabolisme , Dialyse rénale/mortalité , Taux de survie
13.
Biomed Pharmacother ; 61(10): 693-7, 2007 Dec.
Article de Anglais | MEDLINE | ID: mdl-17640846

RÉSUMÉ

Amino groups of amino acids, nucleic acids and lipids can react non-enzymatically with reducing sugars to form unstable Schiff bases that can then undergo the Amadori rearrangement to form irreversible advanced glycation end products (AGEs). Ketoacidosis is a life-threatening complication in patients with untreated diabetes mellitus and it is characterized by increased circulating ketone body concentrations. Recently, the in vitro glycation of hemoglobin by beta-hydroxybutyrate and acetone was described by our laboratory. This study was designed to evaluate the in vitro effect of acetoacetate on brain aminophospholipids at similar concentrations to that observed in ketoacidosis (16.13 mM total ketone bodies). The effect of acetoacetate was compared to that of glucose and the other ketone bodies; beta-hydroxybutyrate and acetone. The antiglycating activity of urea and glycylglycine was also investigated. The incubation of aminophospholipids with acetoacetate results in the formation of a new compound with an absorption peak at 280 nm. When this reaction product was analyzed by thin layer chromatography using an elusion system of methanol:chloroform:acetic acid:water (8:1:1:0.4), the R(f) value obtained (0.24-0.26) was similar to that of the compound formed by aminophospholipids with glucose. In contrast, this reaction product was not detected in those samples containing beta-hydroxybutyrate and acetone. The formation of this new compound was inhibited by urea more effectively than glycylglycine. In conclusion, this study provides the evidence that brain aminophospholipids react with acetoacetate forming AGEs and that this glycating effect of acetoacetate was remarkably decreased by urea, suggesting a protective physiological role for urea in the body as it was previously stated. Finally, this information adds knowledge about the contribution of ketoacidosis in the pathophysiology of diabetic complications, especially in type 1 diabetic patients.


Sujet(s)
Acétoacétates/antagonistes et inhibiteurs , Acétoacétates/pharmacologie , Chimie du cerveau/effets des médicaments et des substances chimiques , Phospholipides/métabolisme , Urée/pharmacologie , Animaux , Bovins , Chromatographie sur couche mince , Glucose/pharmacologie , Produits terminaux de glycation avancée/analyse , Produits terminaux de glycation avancée/composition chimique , Glycylglycine/pharmacologie , Corps cétoniques/pharmacologie , Lipides/composition chimique , Lipides/isolement et purification , Spectrophotométrie UV
14.
Rev Alerg Mex ; 53(6): 212-6, 2006.
Article de Anglais | MEDLINE | ID: mdl-17361755

RÉSUMÉ

BACKGROUND: Hyperglycemia induces protein glycation, disturbing its function, additionally, the glycated products (AGEs) induce by themselves proinflammatory cytokine release that are responsible for insulin resistance. Glycine has been successfully used in diabetic patients to competitively reduce hemoglobin glycation. OBJECTIVES: To assess hyperglycemia impact on the immune response and to evaluate if it is possible to reverse it by means of glycine administration. MATERIAL AND METHODS: Streptozotocin-induced diabetic rats, with and without glycine administration were challenged with sheep red blood cells, and specific antibody producing cells were accounted. Normal rats were challenged as controls. RESULTS: Induced diabetes modifies significantly the humoral immune response capacity versus sheep red blood cells. Also, glycine administration prevents against this deleterious effect. CONCLUSIONS: Glycine could be an important therapeutic resource among diabetics to avoid the characteristic immunodeficiencies of this disease.


Sujet(s)
Production d'anticorps/effets des médicaments et des substances chimiques , Diabète expérimental/immunologie , Glycine/usage thérapeutique , Déficits immunitaires/traitement médicamenteux , Animaux , Cellules productrices d'anticorps/effets des médicaments et des substances chimiques , Cellules productrices d'anticorps/immunologie , Glycémie/analyse , Diabète expérimental/complications , Évaluation préclinique de médicament , Érythrocytes/immunologie , Hémoglobine glyquée/analyse , Produits terminaux de glycation avancée/analyse , Glycine/pharmacologie , Déficits immunitaires/étiologie , Mâle , Rats , Rat Wistar , Ovis , Streptozocine
15.
Diabetologia ; 48(12): 2675-81, 2005 Dec.
Article de Anglais | MEDLINE | ID: mdl-16283249

RÉSUMÉ

AIMS/HYPOTHESIS: To assess the involvement of the AGE-specific receptor (AGER, also known as RAGE) axis and nuclear factor kappa-B (NFKB, also known as NF-kappaB) activation in the development of lacrimal gland and tear film dysfunction in diabetes, the present study evaluated: (1) lacrimal gland and tear film alterations in diabetic rats; and (2) the expression of AGE, AGER and NFKB in ocular tissues of normoglycaemic and diabetic rats. MATERIALS AND METHODS: Diabetes was induced in male Wistar rats with intravenous streptozotocin. Tear secretion parameters were measured and NFKB expression was evaluated in lacrimal glands of control and diabetic rats by western blot. Immunohistochemistry with confocal microscopy was used to assess AGE, AGER and NFKB expression in lacrimal glands of both groups. RESULTS: Lacrimal gland weight and tear film volume were lower in diabetic than in control rats (p=0.01 and 0.02, respectively). IL1B and TNF concentrations in tears were higher in diabetic than in control rats (p=0.007 and 0.02, respectively). NFKB protein was identified in rat cornea, conjunctiva and lacrimal glands. AGE, AGER and NFKB expression were greater in lacrimal glands of diabetic than in those of control rats. CONCLUSIONS/INTERPRETATION: Diabetes induces significant alterations in rat lacrimal gland structure and secretion. The higher expression of AGE, AGER and NFKB in lacrimal glands of diabetic rats suggests that these factors are involved in signalling and in subsequent inflammatory alterations related to dry eye in diabetes mellitus.


Sujet(s)
Diabète expérimental/métabolisme , Produits terminaux de glycation avancée/analyse , Appareil lacrymal/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Récepteurs immunologiques/métabolisme , Animaux , Technique de Western , Conjonctive/métabolisme , Conjonctive/physiopathologie , Cornée/métabolisme , Cornée/physiopathologie , Diabète expérimental/génétique , Diabète expérimental/physiopathologie , Syndromes de l'oeil sec/physiopathologie , Expression des gènes , Produits terminaux de glycation avancée/génétique , Produits terminaux de glycation avancée/métabolisme , Immunohistochimie , Interleukine-1/métabolisme , Appareil lacrymal/physiopathologie , Mâle , Facteur de transcription NF-kappa B/génétique , Rats , Rat Wistar , Récepteur spécifique des produits finaux de glycosylation avancée , Récepteurs immunologiques/génétique , Larmes/métabolisme , Facteur de nécrose tumorale alpha/métabolisme
16.
J Endocrinol ; 187(1): 159-66, 2005 Oct.
Article de Anglais | MEDLINE | ID: mdl-16214951

RÉSUMÉ

Advanced glycation end products (AGEs) increase with aging and induce signaling alterations that lead to inflammation and dysfunction in several tissues. Aging reduces function and insulin signaling in lacrimal glands (LGs). To evaluate whether AGE signaling and insulin secretion in LGs are altered in aging, 24- and 2-month-old male Wistar rats were compared. Immunohistochemistry with confocal microscopy was used to evaluate AGE, AGE receptor (RAGE) and nuclear factor-kappaB (NF-kappaB) expression in LGs. Basal tear secretion volume, insulin, interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) levels in tears and LGs and peroxidase activity in LG tissue were measured. Insulin secretion from isolated LGs and pancreatic beta-cells was compared in the supernatant of aging and control rats in vitro by RIA after stimulation with 2.8-16.7 mM glucose, carbachol and KCl. AGE, RAGE and NF-kappaB expression was higher in LGs of aging compared with young rats. Basal tear secretion and peroxidase activity were significantly lower in the aging group (P=0.016 for both assays). IL-1beta and TNF-alpha levels were higher in tears of aging rats compared with young rats (P=0.007 and 0.05 respectively); however, even though aging rats were insulin-resistant (as confirmed by the insulin-tolerance test), the insulin levels in the tear film of aging and control rats were similar in vivo and in vitro. The higher expression of AGEs, RAGE and NF-kappaB in LGs of aging rats is accompanied by systemic insulin resistance and may be involved in LG and tear film alterations but does not affect insulin secretion in the tear film. These observations indicate that metabolic events may be related to LG and tear film dysfunctions in aging.


Sujet(s)
Vieillissement/physiologie , Produits terminaux de glycation avancée/analyse , Appareil lacrymal/métabolisme , Facteur de transcription NF-kappa B/analyse , Animaux , Carbachol/pharmacologie , Glucose/pharmacologie , Produits terminaux de glycation avancée/métabolisme , Immunohistochimie/méthodes , Insuline/métabolisme , Sécrétion d'insuline , Interleukine-1/analyse , Mâle , Microscopie confocale , Myotiques/pharmacologie , Facteur de transcription NF-kappa B/métabolisme , Techniques de culture d'organes , Pancréas/métabolisme , Myeloperoxidase/analyse , Myeloperoxidase/métabolisme , Chlorure de potassium/pharmacologie , Rats , Rat Wistar , Récepteur spécifique des produits finaux de glycosylation avancée , Récepteurs immunologiques/analyse , Transduction du signal/physiologie , Larmes/composition chimique , Larmes/métabolisme , Facteur de nécrose tumorale alpha/analyse
17.
Clin Chem ; 43(9): 1563-9, 1997 Sep.
Article de Anglais | MEDLINE | ID: mdl-9299934

RÉSUMÉ

We proposed a simple analytical procedure for measurement of serum advanced glycosylation end products (AGEs) based on simultaneous detection of low-molecular-mass peptides and AGEs with a flow system and two detectors connected on-line: spectrophotometric for peptides (lambda = 280 nm) and spectrofluorometric for AGEs (lambda ex = 247 nm, lambda em = 440 nm). Sample pretreatment was carried out in microcentrifuge tubes: Serum (20 microL) was deproteinized with trichloroacetic acid (480 microL, 0.15 mol/L) and lipids were extracted with chloroform (100 microL). Twenty microliters of the filtered aqueous layer was injected to the flow system and the relation between fluorescence and absorption signals was measured. A peptide-derived AGE calibrator was used for calibration. Within-day and between-day CVs were 6.7% and 9.1%, respectively, at an AGE concentration corresponding approximately to that in healthy individuals. Mean results (+/-SD) in 10 healthy individuals were 10.1% +/- 1.0%, in 21 patients with diabetes without complications 18.0% +/- 6.2%, in 25 patients with complications 24.1% +/- 15.4%, and in 12 diabetic patients in end-stage renal disease 92% +/- 30%. Comparison with an ELISA procedure (x, in arbitrary units/L) yields a regression equation y = 0.713x + 1.24 (Sy [symbol: see text] x = 6777, r = 0.8477, n = 41).


Sujet(s)
Diabète/sang , Produits terminaux de glycation avancée/sang , Produits terminaux de glycation avancée/analyse , Humains , Systèmes en direct , Peptides/sang , Peptides/composition chimique , Valeurs de référence , Analyse de régression , Reproductibilité des résultats , Sérumalbumine bovine/analyse , Spectrométrie de fluorescence/méthodes , Spectrophotométrie/méthodes
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE